FDA Approved: EOVIST — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

The FDA has approved Bayer's supplemental application for Eovist (gadoxetate disodium), updating its labeling to expand its use as an MRI contrast agent for ima…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Diseases
• Liver Neoplasms

Drugs mentioned

• EOVIST (GADOXETATE DISODIUM)

Snippet

SUPPL AP for EOVIST (GADOXETATE DISODIUM)